Citations 2
Correction for Schmidt-Malan et al., “ In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli”
Schmidt-Malan, Suzannah M., Mishra, Avisya J., Mushtaq, Ammara , Brinkman, Cassandra L., Patel, Robin , Patel, Robin
Antimicrobial Agents and Chemotherapy | January 28, 2019 | Volume: 63 | Issue: 2 | Pages: No page available
In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli
Schmidt-Malan, Suzannah M., Mishra, Avisya J., Mushtaq, Ammara , Brinkman, Cassandra L., Patel, Robin , Patel, Robin
Antimicrobial Agents and Chemotherapy | May 15, 2018 | Volume: 62 | Issue: 8 | Pages: No page available
Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam–β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli.